Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2001 September; 85(7): 953–958.
PMCID: PMC2375104

The treatment of advanced renal cell cancer with high-dose oral thalidomide


Thalidomide is reported to suppress levels of several cytokines, angiogenic and growth factors including TNF-α, basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6). The resulting anti-angiogenic, immunomodulatory and growth suppressive effects form the rationale for investigating thalidomide in the treatment of malignancies. We have evaluated the use of high-dose oral thalidomide (600 mg daily) in patients with renal carcinoma. 25 patients (all men; median age, 51 years; range 34–76 years) with advanced measurable renal carcinoma, who had either progressed on or were not suitable for immunotherapy, received thalidomide in an escalating schedule up to a maximum dose of 600 mg daily. Treatment continued until disease progression or unacceptable toxicity were encountered. 22 patients were assessable for response. 2 patients showed partial responses (9%; 95% CI: 1–29), 7 (32%; 95% CI: 14–55) had stable disease for more than 6 months and a further 5 (23%; 95% CI: 8–45) had stable disease for between 3 and 6 months. We also measured levels of TNF-α, bFGF, VEGF, IL-6 and IL-12 before and during treatment. In patients with SD ≥ 3 months or an objective response, a statistically significant decrease in serum TNF-α levels was demonstrated (P = 0.05). The commonest toxicities were lethargy (≥ grade II, 10 patients), constipation (≥ grade II, 11 patients) and neuropathy (≥ grade II, 5 patients). Toxicities were of sufficient clinical significance for use of a lower and well tolerated dose of 400 mg in currently accruing studies. © 2001 Cancer Research Campaign

Keywords: thalidomide, renal cell carcinoma

Full Text

The Full Text of this article is available as a PDF (73K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Berger TG, Hoffman C, Thieberg MD. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol. 1995 Nov;33(5 Pt 1):837–838. [PubMed]
  • Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 1995 Aug;72(2):339–343. [PMC free article] [PubMed]
  • D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082–4085. [PubMed]
  • Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000 Feb;82(4):812–817. [PMC free article] [PubMed]
  • Elsässer-Beile U, Grussenmeyer T, Gierschner D, Schmoll B, Schultze-Seemann W, Wetterauer U, Schulte Mönting J. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes. Cancer Immunol Immunother. 1999 Jul;48(4):204–208. [PubMed]
  • Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000 Feb;18(4):708–715. [PubMed]
  • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov 18;285(21):1182–1186. [PubMed]
  • Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995 Dec 28;333(26):1757–1763. [PubMed]
  • Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst. 1999 Oct 6;91(19):1635–1640. [PubMed]
  • FULLERTON PM, KREMER M. Neuropathy after intake of thalidomide (distaval). Br Med J. 1961 Sep 30;2(5256):855–858. [PMC free article] [PubMed]
  • Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol. 1998 Apr;25(2 Suppl 6):53–57. [PubMed]
  • Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997 May 22;336(21):1487–1493. [PubMed]
  • Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso CL, deKernion JB, Belldegrum A. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother. 1992;35(2):97–105. [PubMed]
  • König B, Steinbach F, Janocha B, Drynda A, Stumm M, Philipp C, Allhoff EP, König W. The differential expression of proinflammatory cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma. Anticancer Res. 1999 Mar-Apr;19(2C):1519–1524. [PubMed]
  • La Maestra L, Zaninoni A, Marriott JB, Lazzarin A, Dalgleish AG, Barcellini W. The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clin Exp Immunol. 2000 Jan;119(1):123–129. [PubMed]
  • Lopez Hänninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol. 1996 Jan;155(1):19–25. [PubMed]
  • Mitsuyasu RT. Update on the pathogenesis and treatment of Kaposi sarcoma. Curr Opin Oncol. 2000 Mar;12(2):174–180. [PubMed]
  • O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21;79(2):315–328. [PubMed]
  • O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997 Jan 24;88(2):277–285. [PubMed]
  • Raje N, Anderson K. Thalidomide--a revival story. N Engl J Med. 1999 Nov 18;341(21):1606–1609. [PubMed]
  • Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer. 1996 Dec;32A(14):2438–2450. [PubMed]
  • Rhodes J, Thomas G, Evans BK. Inflammatory bowel disease management. Some thoughts on future drug developments. Drugs. 1997 Feb;53(2):189–194. [PubMed]
  • Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993 Aug;168(2):408–414. [PubMed]
  • Sands BE, Podolsky DK. New life in a sleeper: thalidomide and Crohn's disease. Gastroenterology. 1999 Dec;117(6):1485–1488. [PubMed]
  • Sauer H, Günther J, Hescheler J, Wartenberg M. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am J Pathol. 2000 Jan;156(1):151–158. [PubMed]
  • Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565–1571. [PubMed]
  • Stephens TD, Fillmore BJ. Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology. 2000 Mar;61(3):189–195. [PubMed]
  • Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw RJ. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med. 1997 Jan;91(1):31–39. [PubMed]
  • Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992 Dec 1;52(23):6702–6704. [PubMed]
  • Teicher BA, Holden SA, Ara G, Korbut T, Menon K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol. 1996;38(2):169–177. [PubMed]
  • Thiel R, Kastner U, Neubert R. Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative. Life Sci. 2000;66(2):133–141. [PubMed]
  • Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992 Apr 16;326(16):1055–1058. [PubMed]
  • Weidmann E, Bergmann L, Stock J, Kirsten R, Mitrou PS. Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother (1991) 1992 Aug;12(2):123–131. [PubMed]
  • Yoneda T, Alsina MA, Chavez JB, Bonewald L, Nishimura R, Mundy GR. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. J Clin Invest. 1991 Mar;87(3):977–985. [PMC free article] [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK